R
Robert A. Rosenheck
Researcher at Yale University
Publications - 993
Citations - 58354
Robert A. Rosenheck is an academic researcher from Yale University. The author has contributed to research in topics: Mental health & Veterans Affairs. The author has an hindex of 114, co-authored 963 publications receiving 54357 citations. Previous affiliations of Robert A. Rosenheck include Eastern Virginia Medical School & The Feinstein Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe,Robert M. Bilder,Sonia M. Davis,Philip D. Harvey,Barton W. Palmer,James M. Gold,Herbert Y. Meltzer,Michael F. Green,George Capuano,T. Scott Stroup,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Clarence E. Davis,John K. Hsiao,Jeffrey A. Lieberman +16 more
TL;DR: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.
Journal ArticleDOI
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
Joseph P. McEvoy,Jeffrey A. Lieberman,T. Scott Stroup,Sonia M. Davis,Herbert Y. Meltzer,Robert A. Rosenheck,Marvin S. Swartz,Diana O. Perkins,Richard S.E. Keefe,Clarence E. Davis,Joanne B. Severe,John K. Hsiao +11 more
TL;DR: For patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypicals antipsychotics.
Journal ArticleDOI
A National Study of Violent Behavior in Persons With Schizophrenia
Jeffrey W. Swanson,Marvin S. Swartz,Richard A. Van Dorn,Eric B. Elbogen,H. Ryan Wagner,Robert A. Rosenheck,T. Scott Stroup,Joseph P. McEvoy,Jeffrey A. Lieberman +8 more
TL;DR: To examine the prevalence and correlates of violence among schizophrenia patients living in the community by developing multivariable statistical models to assess the net effects of psychotic symptoms and other risk factors for minor and serious violence, a large number of patients diagnosed as having schizophrenia were enrolled.
Journal ArticleDOI
Compliance With Medication Regimens for Mental and Physical Disorders
TL;DR: Compliance with medication regimens among patients with psychiatric disorders may be lower than among Patients with physical disorders, however, the difference may be largely attributable to the methods used for estimating compliance.